# US 2026/0209772 A1 · Novel rna therapeutics and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0209772 A1
- Document ID: US20260209772A1
- Status: Published application
- Kind: A1
- Application number: 19/141,216
- Filed: 2023-12-22
- Published: 2026-07-23
- Earliest claimed: 2022-12-23
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Patrick Joseph ANTONELLIS; Thomas Patrick BEYER; Jean Mawuena BRANTTIE; Christine Chih-Tao CHENG; Marjoke F. DEBETS; Konstantinos GAVARDINAS; Gregory Lawrence LACKNER; Jibo WANG; Takako WILSON
- Web page: https://patentgrep.com/patent/US20260209772A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61P 3/06: Antihyperlipidemics
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12Y 101/01034: Hydroxymethylglutaryl-CoA reductase (NADPH) (1.1.1.34)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/351: Conjugate
- C12N 2310/3521: Methyl
- C12N 2310/3533: Halogen
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present disclosure relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the HMGCR receptor (expressed by the HMGCR gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases and disorders involving the regulation of HMGCR expression and function, such as diseases and disorders that are risk factors for ASCVD (such as, dyslipidemia, such as hypercholesteremia).

## Claims

### Claim 1

An RNAi agent for reducing HMGCR gene expression, wherein the RNAi agent comprises a delivery moiety of Formula I conjugated to R, wherein R is a double stranded RNA (dsRNA) comprising an antisense strand and a sense strand:
wherein R is conjugated to connection point E of Formula I, optionally via a linker, wherein the sense strand and the antisense strand form a duplex region, and wherein the antisense strand comprises a region of complementarity to a HMGCR mRNA target sequence of SEQ ID NO: 1, and wherein the sense and antisense strand each optionally comprise one or more modified nucleotides and one or more modified internucleotide linkages.

### Claim 2 (depends on 1)

The RNAi agent of claim 1, wherein Formula I is conjugated to the 3′ terminal nucleotide of the sense strand, optionally via a linker.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand is 15 to 50 nucleotides in length.

### Claim 5 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand is 15 to 50 nucleotides in length.

### Claim 6 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand is between 18 and 23 nucleotides in length.

### Claim 7 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand is between 18 and 21 nucleotides in length.

### Claim 8 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand is 23 nucleotides in length and the sense strand is 21 nucleotides in length.

### Claim 9 (depends on 1)

The RNAi agent of claim 1, wherein the region of complementarity is at least 18 nucleotides in length.

### Claim 10 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand comprises a sequence selected from the group consisting of SEQ ID NOs: 2 to 387.

### Claim 11 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand has a nucleotide sequence selected from the group consisting of SEQ ID NOs: 774 to 1159, or a sequence having at least 90% sequence identity thereto.

### Claim 12 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand is selected from the group consisting of SEQ ID NOs: 388 to 773, or a sequence having at least 90% sequence identity thereto.

### Claim 13 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand or the antisense strand each independently comprise one or more modified nucleotides, and the modified nucleotides are independently 2′ fluoro modified nucleotide residues or 2′-O-methyl modified nucleotides.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The RNAi agent of claim 1, wherein each nucleotide of the sense strand and each nucleotide of the antisense strand is a modified nucleotide.

### Claim 16 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand is 23 nucleotides in length and wherein each nucleotide of the antisense strand is a modified nucleotide, and 2′ fluoro modified nucleotides are present at
a. positions 2, 3, 7, 14, and 16 from the 5′ end of the antisense strand; or
b. positions 2, 5, 7, 14, and 16 from the 5′ end of the antisense strand; or
c. Positions 2, 3, 8, 14, and 16 from the 5′ end of the antisense strand; or
d. Positions 2, 5, 8, 14, and 16 from the 5′ end of the antisense strand; or
e. Positions 2, 6, 14, and 16 from the 5′ end of the antisense strand.

### Claim 17 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand and antisense strand each independently comprise one or more modified internucleotide linkages, and wherein each modified internucleotide linkage is a phosphorothioate linkage.

### Claim at position 18

-19. (canceled)

### Claim 20 (depends on 1)

The RNAi agent of claim 1, wherein the antisense strand comprises a sequence selected from the group consisting of SEQ ID NOs: 1161, 1163, 1165, 1167, 1169, 1171, 1173, 1175, 1177, 1179, 1181, 1183, 1185, 1187, 1189, 1191, 1193, 1195, 1197, 1199, 1201, 1203, 1205, 1207, 1209, 1211, 1213, 1215, 1217, 1219, 1221, 1223, 1225, 1227, 1229, 1231, 1233, 1235, 1237, 1239, 1241, 1243, 1245, 1247, 1249, 1251, 1253, 1255, 1257, 1259, 1261, 1263, 1265, 1267, 1269, 1271, 1273, 1275, 1277, 1279, 1281, 1283, 1285, 1287, 1289, 1291, 1293, 1295, 1297, 1299, 1301, 1303, 1305, 1307, 1309, 1311, 1313, 1315, 1317, 1319, 1321, 1323, 1325, 1327, 1329, 1331, 1333, 1335, 1337, 1339, 1341, 1343, 1345, 1347, 1349, 1351, 1353, 1355, 1357, 1359, 1361, 1363, 1365, 1367, 1369, 1371, 1373, 1375, 1377, 1379, 1381, 1383, 1385, 1387, 1389, 1391, 1393, 1395, 1397, 1399, 1401, 1403, 1405, 1407, 1409, 1411, 1413, 1415, 1417, 1419, 1421, 1423, 1425, 1427, 1429, 1431, 1433, 1435, 1437, 1439, 1441, 1443, 1445, 1447, 1449, 1451, 1453, 1455, 1457, 1459, 1461, 1463, 1465, 1467, 1469, 1471, 1473, 1475, 1477, 1479, 1481, 1483, 1485, 1487, 1489, 1491, 1493, 1495, 1497, 1499, 1501, 1503, 1505, 1507, 1509, 1511, 1513, 1515, 1517, 1519, 1521, 1523, 1525, 1527, 1529, 1531, 1533, 1535, 1537, 1539, 1541, 1543, 1545, 1547, 1549, 1551, 1553, 1555, 1557, 1559, 1561, 1563, 1565, 1567, 1569, 1571, 1573, 1575, 1577, 1579, 1581, 1583, 1585, 1587, 1589, 1591, 1593, 1595, 1597, 1599, 1601, 1603, 1605, 1607, 1609, 1611, 1613, 1615, 1617, 1619, 1621, 1623, 1625, 1627, 1629, 1631, 1633, 1635, 1637, 1639, 1641, 1643, 1645, 1647, 1649, 1651, 1653, 1655, 1657, 1659, 1661, 1663, 1665, 1667, 1669, 1671, 1673, 1675, 1677, 1679, 1681, 1683, 1685, 1687, 1689, 1691, 1693, 1695, 1697, 1699, 1701, 1703, 1705, 1707, 1709, 1711, 1713, 1715, 1717, 1719, 1721, 1723, 1725, 1727, 1729, 1731, 1733, 1735, 1737, 1739, 1741, 1743, 1745, 1747, 1749, 1751, 1753, 1755, 1757, 1759, 1761, 1763, 1765, 1767, 1769, 1771, 1773, 1775, 1777, 1779, 1781, 1783, 1785, 1787, 1789, 1791, 1793, 1795, 1797, 1799, 1801, 1803, 1805, 1807, 1809, 1811, 1813, 1815, 1817, 1819, 1821, 1823, 1825, 1827, 1829, 1831, 1833, 1835, 1837, 1839, 1841, 1843, 1845, 1847, 1849, 1851, 1853, 1855, 1857, 1859, 1861, 1863, 1865, 1867, 1869, 1871, 1873, 1875, 1877, 1879, 1881, 1883, 1885, 1887, 1889, 1891, 1893, 1895, 1897, 1899, 1901, 1903, 1905, 1907, 1909, 1911, 1913, 1915, 1917, 1919, 1921, 1923, 1925, 1927, 1929, 1931, or a sequence having at least 90% sequence identity thereto, wherein the 5′ terminal nucleotide of the antisense strand comprises a vinyl phosphonate, a phosphate, or a hydroxyl group.

### Claim 21

(canceled)

### Claim 22 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises a sequence selected from the group consisting of SEQ ID NOs: 1160, 1162, 1164, 1166, 1168, 1170, 1172, 1174, 1176, 1178, 1180, 1182, 1184, 1186, 1188, 1190, 1192, 1194, 1196, 1198, 1200, 1202, 1204, 1206, 1208, 1210, 1212, 1214, 1216, 1218, 1220, 1222, 1224, 1226, 1228, 1230, 1232, 1234, 1236, 1238, 1240, 1242, 1244, 1246, 1248, 1250, 1252, 1254, 1256, 1258, 1260, 1262, 1264, 1266, 1268, 1270, 1272, 1274, 1276, 1278, 1280, 1282, 1284, 1286, 1288, 1290, 1292, 1294, 1296, 1298, 1300, 1302, 1304, 1306, 1308, 1310, 1312, 1314, 1316, 1318, 1320, 1322, 1324, 1326, 1328, 1330, 1332, 1334, 1336, 1338, 1340, 1342, 1344, 1346, 1348, 1350, 1352, 1354, 1356, 1358, 1360, 1362, 1364, 1366, 1368, 1370, 1372, 1374, 1376, 1378, 1380, 1382, 1384, 1386, 1388, 1390, 1392, 1394, 1396, 1398, 1400, 1402, 1404, 1406, 1408, 1410, 1412, 1414, 1416, 1418, 1420, 1422, 1424, 1426, 1428, 1430, 1432, 1434, 1436, 1438, 1440, 1442, 1444, 1446, 1448, 1450, 1452, 1454, 1456, 1458, 1460, 1462, 1464, 1466, 1468, 1470, 1472, 1474, 1476, 1478, 1480, 1482, 1484, 1486, 1488, 1490, 1492, 1494, 1496, 1498, 1500, 1502, 1504, 1506, 1508, 1510, 1512, 1514, 1516, 1518, 1520, 1522, 1524, 1526, 1528, 1530, 1532, 1534, 1536, 1538, 1540, 1542, 1544, 1546, 1548, 1550, 1552, 1554, 1556, 1558, 1560, 1562, 1564, 1566, 1568, 1570, 1572, 1574, 1576, 1578, 1580, 1582, 1584, 1586, 1588, 1590, 1592, 1594, 1596, 1598, 1600, 1602, 1604, 1606, 1608, 1610, 1612, 1614, 1616, 1618, 1620, 1622, 1624, 1626, 1628, 1630, 1632, 1634, 1636, 1638, 1640, 1642, 1644, 1646, 1648, 1650, 1652, 1654, 1656, 1658, 1660, 1662, 1664, 1666, 1668, 1670, 1672, 1674, 1676, 1678, 1680, 1682, 1684, 1686, 1688, 1690, 1692, 1694, 1696, 1698, 1700, 1702, 1704, 1706, 1708, 1710, 1712, 1714, 1716, 1718, 1720, 1722, 1724, 1726, 1728, 1730, 1732, 1734, 1736, 1738, 1740, 1742, 1744, 1746, 1748, 1750, 1752, 1754, 1756, 1758, 1760, 1762, 1764, 1766, 1768, 1770, 1772, 1774, 1776, 1778, 1780, 1782, 1784, 1786, 1788, 1790, 1792, 1794, 1796, 1798, 1800, 1802, 1804, 1806, 1808, 1810, 1812, 1814, 1816, 1818, 1820, 1822, 1824, 1826, 1828, 1830, 1832, 1834, 1836, 1838, 1840, 1842, 1844, 1846, 1848, 1850, 1852, 1854, 1856, 1858, 1860, 1862, 1864, 1866, 1868, 1870, 1872, 1874, 1876, 1878, 1880, 1882, 1884, 1886, 1888, 1890, 1892, 1894, 1896, 1898, 1900, 1902, 1904, 1906, 1908, 1910, 1912, 1914, 1916, 1918, 1920, 1922, 1924, 1926, 1928, 1930, or a sequence having at least 90% sequence identity thereto.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises a sequence selected from the group consisting of SEQ ID NOs: 1932-2317, or a sequence having at least 90% sequence identity thereto.

### Claim 25 (depends on 1)

The RNAi agent of claim 1, wherein the sense strand comprises a sequence selected from the group consisting of SEQ ID NOs: 1932-2317, or a sequence having at least 95% sequence identity thereto.

### Claim 26 (depends on 1)

The RNAi agent of claim 1, wherein the RNAi agent antisense strand comprises a first nucleic acid sequence that has at least 90% sequence identity to an antisense sequence of any one of Duplex NOs: 387-772 in Table 4A, and the sense strand comprises a second nucleic acid sequence that has at least 90% sequence identity to a sense sequence of the same Duplex in Table 4A.

### Claim 27 (depends on 1)

The RNAi agent of claim 1, wherein the RNAi agent antisense strand comprises a first nucleic acid sequence that has at least 90% sequence identity to an antisense sequence of any one of Duplex NOs: 773-1158 in Table 4B, and the sense strand comprises a second nucleic acid sequence that has at least 90% sequence identity to a sense sequence of the same Duplex in Table 4B.

### Claim at position 27

-29. (canceled)

### Claim 30 (depends on 1)

The RNAi agent of claim 1, wherein R is conjugated to Formula I via a linker, and wherein linker comprises Formula II having connection points A and B or the linker comprises Formula III having connection points C and D, and wherein:
a. Formula I at connection point E is conjugated to Formula II at connection point A and Formula II is conjugated to a phosphate group or a phosphorothioate group at connection point B, and the phosphate group or phosphorothioate group is conjugated to R; or
b. Formula I at connection point E is conjugated to Formula III at connection point C and Formula III is conjugated to a phosphate group or phosphorothioate group at connection point D, and the phosphate group or phosphorothioate group is further conjugated to R.

### Claim 31 (depends on 1)

The RNAi agent of claim 1, wherein R is conjugated to Formula I via a linker, and wherein the linker comprises Formula III having connection points C and D:
wherein Formula I at connection point E is conjugated to Formula III at connection point C and Formula III is conjugated to a phosphate group or a phosphorothioate group at connection point D, and the phosphate group or the phosphorothioate group is further conjugated to R.

### Claim 32 (depends on 1)

A pharmaceutical composition comprising the RNAi agent of claim 1, and one or more pharmaceutically acceptable excipients.

### Claim at position 31

-41. (canceled)

### Claim 42 (depends on 1)

A method of treating a disease or disorder associated with ASCVD in a patient in need thereof, comprising administering to the patient the RNAi agent of claim 1, or a pharmaceutical composition thereof.

### Claim 43 (depends on 42)

The method of claim 42, wherein the disease or disorder is dyslipidemia, primary dysbetalipoproteinemia, hypertriglyceridemia, or atherosclerosis.

### Claim 44 (depends on 42)

The method of claim 42, wherein the disease or disorder is dyslipidemia.

### Claim 45 (depends on 44)

The method of claim 44, wherein the dyslipidemia is hypercholesterolemia.

### Claim 46 (depends on 1)

A method of decreasing HMGCR expression in a cell, comprising contacting the cell with the RNAi agent of claim 1.

### Claim 47 (depends on 46)

The method of claim 46, wherein the method further comprises incubating the cell for a time sufficient for decreasing the level of HMGCR mRNA by at least 50% as compared to an untreated or control treated cell.
